Form 4: Galera Therapeutics CEO Reports Stock Transaction
Insider Transaction (Form 4)
Mel Sorensen, President and CEO and a Director of Galera Therapeutics, Inc., reported multiple transactions in common stock on August 3, 2026.
Summary
- Disposition to the issuer: disposed of 975 Common Stock on August 3, 2026 (Direct).
- Disposition to the issuer: disposed of 30,000 Stock Option (Right to Buy) on August 3, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Mel Sorensen — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-03 | Disposition to the issuer | Common Stock | 975 | — | — | 0 |
| 2026-08-03 | Disposition to the issuer | Stock Option (Right to Buy) | 30,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-03 | Disposition to the issuer (975 shares) |
| 2026-08-03 | Disposition to the issuer (30,000 shares) |
Keywords
insider transaction, Form 4, GRTX, Galera Therapeutics, Inc., neutral, Mel Sorensen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.